ACC 2023热点速递：降脂治疗与心血管保护

详细信息

收稿日期: 2023-03-12

刊出日期: 2023-04-13

Highlights from ACC 2023: lipid-lowering therapy and cardiovascular protection

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Received Date: 12 March 2023

Publish Date: 13 April 2023

摘要: 血脂管理是治疗动脉粥样硬化性心血管疾病，改善疾病预后的基石治疗。2023年度美国心脏病学会科学会议聚焦于降脂治疗与心血管保护这一主题，公布了多个新的临床研究结果。
- 动脉粥样硬化性心血管疾病 /
- 高脂血症 /
- 降脂治疗 /
- 他汀 /
- PCSK9抑制剂
Abstract: Lipid-lowering therapy is essential for treating atherosclerotic cardiovascular disease and preventing cardiovascular events. Here we summarized the new data from the key clinical trials presented at the American College of Cardiology(ACC) 2023 annual scientific sessions, which focus on the effects of lipid-lowering therapy on cardiovascular protection.
- atherosclerotic cardiovascular disease /
- hyperlipidemia /
- lipid-lowering therapy /
- statin /
- PCSK9 inhibitor

[1]	Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials[J]. Lancet, 2023.
[2]	Neilan TG, et al. STOP-CA Trial: Statin Therapy Associated With Reduced Heart Dysfunction From Anthracyclines[R]. In: New Orleans, Louisiana. American College of Cardiology(ACC)2023 Annual Scientific Sessions. 2023.
[3]	Kini AS, et al. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study(The YELLOW Ⅲ Study)[R]. In: New Orleans, Louisiana. American College of Cardiology(ACC)2023 Annual Scientific Sessions. 2023.
[4]	Ballantyne CM, Banka P, Mendez G, et al. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial[J]. J Am Coll Cardiol, 2023.
[5]	Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients[J]. N Engl J Med, 2023.